Clinical Trials | May 21, 2024
Modular ATP study of the mCRM System meets primary safety and efficacy endpoints
Additional data from APPRAISE ATP trial reinforce modular therapy approach
Additional data from APPRAISE ATP trial reinforce modular therapy approach
95.7% of patients responded to Breyanzi in the TRANSCEND FL trial
Data showed that the primary endpoint of recurrence-free survival (RFS) met the pre-specified futility criteria
EBITDA before special items falls 1.3 percent to € 4.41 billion
Aptar Closures’ E-Disc Top securely protects against in-transit leakage while eliminating the need for liners and extra shipping preparation fees
The brand has also unveiled a new TVC campaign in Telangana and Andhra Pradesh to drive brand awareness
TIVDAK is the first antibody-drug conjugate (ADC) to have positive overall survival data for patients with previously treated recurrent or metastatic cervical cancer
The drug will be manufactured at the group's topical manufacturing facility at Changodar, Ahmedabad (India)
Sales reflect continued strong growth in oncology and vaccines
ALPHA Phase III trial showed first-in-class, oral, Factor D inhibitor as add-on to Ultomiris or Soliris improved haemoglobin levels and reduced anaemia and fatigue
Subscribe To Our Newsletter & Stay Updated
